Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Advanced Medicine

Allogenic Advance

A step closer to an off-the-shelf CAR T cell therapy

James Strachan | | Quick Read

Two-out-of-four patients in a 300 million-cell cohort, and one-out-of-three in a 100-cell cohort, achieved a complete response following treatment with CRISPR Therapeutics’ allogeneic CAR T cell therapy CTX110 (1). 

The B-cell malignancy treatment was safe at the 300-million dose level and below. The only patient who received a 600 million-cell dose, after initially achieving a complete response, was hospitalized with febrile neutropenia and later died after reactivation of HHV-6 and HHV-6 encephalitis.

CTX110 is derived from healthy donor T cells, which are modified using CRISPR/Cas 9 to i) insert a CAR construct, which binds to cancer cells and activates T cells and ii) knock out the T cell receptor and MHC1, which reduces the risk of graft versus host disease and rejection.

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE!

Login

Forgot your password?

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

Manufacture Advanced Medicine
  2. CRISPR Therapeutics (2020). Available at: bit.ly/2TxT5Ag

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Related Webinars

Manufacture Vaccines

Unleashing the Power of Cyclodextrins in Vaccines

| Sponsored by Roquette

Manufacture Advanced Medicine

Fiber-based chromatography to improve productivity in downstream AAV processing

| Sponsored by Cytiva

Manufacture Advanced Medicine

Efficient production process for adeno-associated viral vectors

| Sponsored by Cytiva

Most Popular

1. Business & Regulation Business Practice

Crafting a Culture of Excellence

| Maryam Mahdi

2. Business & Regulation Business Practice

Stemming the Brain Drain

| Kelly Chibale

3. Business & Regulation Business Practice

Building a Beautiful Biotech

| James Strachan

4. Manufacture Formulation

The Rise of Lipid Nanoparticles

| Rahul Keswani, Benjamin King

5. Discovery & Development Drug Delivery

Melt in the Mouth

| Elizabeth Hickman

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

December Issue of The Medicine Maker